The RosetteSepTM CTC Enrichment Cocktail—which targets CD2, CD16, CD19, CD38, CD45, CD66b, GYPA, and either CD36 or CD56 depending on tumour origin—is also currently on the market32, 33. This evidence concerns the gene CD2 and neoplasm.